We are live on ! Find out more
AST

Asterias Biotherapeutics Inc. Series A
AST

Delisted

AST was delisted on the 7th of March, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in Asterias Biotherapeutics Inc. Series A in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 46 → 0 (-46)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $4.73M → $0 (-$4.73M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 46

Holders
–
Holders Change
-46
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
46
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BC
Broadwood Capital
New York
-$3.28M
2
NFC
Northeast Financial Consultants
Connecticut
-$358K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$251K
4
Renaissance Technologies
Renaissance Technologies
New York
-$206K
5
BlackRock
BlackRock
New York
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadwood Capital
New York
– -$3.28M -5,292,156 Closed
NFC
2
Northeast Financial Consultants
Connecticut
– -$358K -577,262 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$251K -405,474 Closed
Renaissance Technologies
4
Renaissance Technologies
New York
– -$206K -332,333 Closed
BlackRock
5
BlackRock
New York
– -$131K -210,981 Closed
Creative Planning
6
Creative Planning
Kansas
– -$124K -200,189 Closed
BCM
7
Bridgeway Capital Management
Texas
– -$115K -186,254 Closed
Millennium Management
8
Millennium Management
New York
– -$81K -130,155 Closed
Geode Capital Management
9
Geode Capital Management
Massachusetts
– -$78K -126,959 Closed
Northern Trust
10
Northern Trust
Illinois
– -$28K -45,135 Closed
Citadel Advisors
11
Citadel Advisors
Florida
– -$22K -35,597 Closed
WJA
12
Williams Jones & Associates
New York
– -$19K -30,100 Closed
RJFSA
13
Raymond James Financial Services Advisors
Florida
– -$9K -14,630 Closed
ARTA
14
A.R.T. Advisors
New York
– -$8K -13,455 Closed
Bank of New York Mellon
15
Bank of New York Mellon
New York
– -$7K -11,973 Closed
Morgan Stanley
16
Morgan Stanley
New York
– -$5K -8,091 Closed
FCMT
17
Founders Capital Management (Texas)
Texas
– -$4K -7,000 Closed
Fifth Third Bancorp
18
Fifth Third Bancorp
Ohio
– -$1K -2,000 Closed
Simplex Trading
19
Simplex Trading
Illinois
– -$1K -1,842 Closed
BNP Paribas Financial Markets
20
BNP Paribas Financial Markets
France
– -$962 -1,552 Closed
IA
21
IFP Advisors
Florida
– -$1K -1,518 Closed
APA
22
American Portfolios Advisors
New York
– -$12 -20 Closed

AST Hedge Fund Activity: Q1 2019 in Review

0 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2019, worth a combined $0 — down 100% from $4.73M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of AST and 0 opened new positions — a net loss of 46 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Broadwood Capital, exiting entirely with an estimated $3.28M sold.

  • 0 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2019, down from 46 in Q4 2018.
  • Funds reported $0 of Asterias Biotherapeutics Inc. Series A stock for Q1 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2019 and 46 closed out, a net change of -46 holders.
  • The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2019 was Broadwood Capital, an estimated $3.28M sold.

Based on aggregated 13F filings for Q1 2019.